1. Home
  2. BNL vs EWTX Comparison

BNL vs EWTX Comparison

Compare BNL & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadstone Net Lease Inc.

BNL

Broadstone Net Lease Inc.

HOLD

Current Price

$19.83

Market Cap

3.8B

Sector

Real Estate

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$30.59

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNL
EWTX
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.3B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
BNL
EWTX
Price
$19.83
$30.59
Analyst Decision
Buy
Buy
Analyst Count
9
6
Target Price
$20.22
$39.00
AVG Volume (30 Days)
3.8M
899.6K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
5.87%
N/A
EPS Growth
N/A
N/A
EPS
0.50
N/A
Revenue
$454,138,000.00
N/A
Revenue This Year
$7.93
N/A
Revenue Next Year
$5.45
N/A
P/E Ratio
$39.75
N/A
Revenue Growth
5.17
N/A
52 Week Low
$15.28
$12.31
52 Week High
$20.48
$35.00

Technical Indicators

Market Signals
Indicator
BNL
EWTX
Relative Strength Index (RSI) 53.85 43.70
Support Level $19.72 $28.72
Resistance Level $20.48 $31.28
Average True Range (ATR) 0.34 1.47
MACD -0.03 -0.43
Stochastic Oscillator 25.29 7.93

Price Performance

Historical Comparison
BNL
EWTX

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: